Smriti Mishra

Smriti Mishra

Auto-generated profile, based on publicly available information

Smriti Mishra

Amity Institute of Biotechnology, Amity University Maharashtra, Mumbai-Pune Expressway, Bhatan, Post Somathne, Panvel 410206, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2023 in Journal of Gastrointestinal Cancer
Verified
Journal Article
Closed access
SMSmriti Mishra
Smriti Mishra
GTGaurang Telang
Gaurang Telang
DBDarpan Bennur
Darpan Bennur
SCShruti Chougule
Shruti Chougule
PDP. B. Dandge
P. B. Dandge
NVNishant Vyas
Nishant Vyas

30 July 2025 in Current Problems in Cancer
Verified
Journal Article
Closed access
GTGaurang Telang
Gaurang Telang
SMSmriti Mishra
Smriti Mishra
ASAnurag Sureshbabu
Anurag Sureshbabu
SKSamruddhi Kulkarni
Samruddhi Kulkarni
SJShantanu Joshi
Shantanu Joshi
RSRajshri Singh
Rajshri Singh

28 February 2025 in Gene Reports
Verified
Journal Article
Closed access
GTGaurang Telang
Gaurang Telang
SMSmriti Mishra
Smriti Mishra
ASAnurag Sureshbabu
Anurag Sureshbabu
SCSameer Chiloo
Sameer Chiloo
SJShantanu Joshi
Shantanu Joshi
STSenthil Thyagarajan
Senthil Thyagarajan

8 August 2022 in Regenerative Engineering and Translational Medicine
Verified
Journal Article
Closed access
PDF file
NBNilaja Badodekar
Nilaja Badodekar
SMSmriti Mishra
Smriti Mishra
GTGaurang Telang
Gaurang Telang
SCShruti Chougule
Shruti Chougule
DBDarpan Bennur
Darpan Bennur
NVNishant Vyas
Nishant Vyas

30 January 2026 in Human Immunology
Verified
Journal Article
Closed access
SMSmriti Mishra
Smriti Mishra
GTGaurang Telang
Gaurang Telang
ASAnurag Sureshbabu
Anurag Sureshbabu
SKSamruddhi Kulkarni
Samruddhi Kulkarni
STSenthil Thayagrajan
Senthil Thayagrajan
RSRajshri Singh
Rajshri Singh

18 December 2025 in Exploration of Immunology
Verified
Journal Article
Open access
PDF file
GTGaurang Telang
Gaurang Telang
SMSmriti Mishra
Smriti Mishra
ASAnurag Sureshbabu
Anurag Sureshbabu
SKSamruddhi Kulkarni
Samruddhi Kulkarni
YBYashoda H. Barage
Yashoda H. Barage
RSRajshri Singh
Rajshri Singh
Aim: To determine whether PepTivator® melanoma-associated antigen-A3 (MAGE-A3) primes early T-cell activation and memory skewing in human peripheral blood mononuclear cells (PBMCs). Methods: PBMCs from 10 donors were stimulated with MAGE-A3 (manufacturer-recommended dose), negative control (NC), or CD3/CD28 and CytoStim™ (PC: positive control). Activation [CD69, CD25, HLA-DR (human leukocyte antigen-DR isotype)], proliferation, cytokines [24 h; GM-CSF (granulocyte-macrophage colony-stimulating factor), IFN-γ (interferon-gamma), IL-2 (interleukin-2), TNF-α (tumor necrosis factor-alpha)], and memory phenotypes (CD45RO/CD27 at days 0/7/14) were quantified by flow cytometry and MACSPlex. Paired statistics used repeated-measures models with Šidák correction; cytokines were analyzed on log10 scale. Results: MAGE-A3 significantly increased early activation (CD69 ↑, CD25 ↑) and modestly increased proliferation, with selective IL-2/TNF-α rise and minimal IFN-γ and modest HLA-DR. Across two weeks, 6/10 donors showed increased central memory T cell (TCM)/effector memory T cell (TEM) with a corresponding decline in naïve cells relative to NC. Variability across donors was evident. Conclusions: MAGE-A3 primes partial activation and memory skewing of human T cells in vitro, suggesting utility as a component antigen that likely benefits from professional antigen-presenting cell (APC) presentation and/or costimulation. We discuss limitations (single dose, in vitro context, donor variability) and implications for future dose-response, HLA-stratified, and APC-supported studies.